Possible genetic polymorphisms related to sex steroid metabolism and dementia in women

Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies

Volumn , Issue , 2009, Pages 143-152

  Hogervorst, Eef ^a   Bandelow, Stephan ^a   Talbot, Chris ^b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949503083     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511635700.016     Document Type: Chapter

References (60)

1. Hogervorst E. The short-lived effect of hormone therapy on cognition function. In Rasgon N, ed. The Effects of Estrogen on Brain Function. Baltimore: Johns Hopkins Press, 2006, pp. 46-78.
2. Yesufu A, Bandelow S, Hogervorst E. Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. Women’s Health. 2007; 3(2):173-95.
3. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women. Neurology. 2000; 54(January 2):295-301.
4. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD. Neurology. 2000; 54(January 1):2061-66.
5. Mulnard RA, Cotman CW, Kawas C. et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s disease. JAMA. 2000; 283:1007-15.
6. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003; 289:2651-62.
7. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291(24):2947-58.
8. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289(20):2663-72.
9. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291 (24):2959-68.
10. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. JAMA. 2004; 291(1):47-53.
11. Henderson VW, Benke KS, Green RC, et al. Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age. JNNP. 2005;76 (1):103-5.
12. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women the Cache County Study. JAMA. 2002;288(17):2123-9.
13. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-57.
14. Nappi RE, Sinforiani E, Mauri M, et al. Memory functioning at menopause impact of age in ovariectomized women. Gynecol Obstet Invest. 1999;47:29-36.
15. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11): 1074-83.
16. Szklo M, Cerhan J, Diez-Roux AV, et al. Estrogen replacement therapy and cognitive functioning in the artherosclerotic risk in communities (ARIC) study. Am J Epidemiol. 1996;144:1048-57.
17. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women II. Results of therapy after 18 months. J Gerontol. 1954;9(2):168-74.
18. Honjo H, Ogino Y, Tanaka K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer’s type: a placebo-controlled double-blind study. J Jpn Menopause Soc. 1993;1:161-71.
19. Birge SJ. The role of estrogen in the treatment of Alzheimer’s disease. Neurology. 1997;48: S36-S41.
20. Zhang YX, Luo G, Guo ZJ, Wang LQ, Zhou CL. Quantitative evaluation of the intervention of estrogen on Alzheimer’s disease. Chin J Clin Rehab. 2006; 10(30):37-91.
21. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroedocrine response to transdermal estrogen in postmenopausal women with AD: results of a placebo-controlled, double-blind pilot study. Psychoneuroendocrinology. 1999;24:657-77.
22. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001;57(4):605-12.
23. Asthana S, Craft S, Baker LD, et al. Transdermal estrogen improves memory in women with Alzheimer’s Disease. Soc Neurosci Abstr. 1996; 22: A200
24. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience. 2000; 101(3):485-512.
25. Hogervorst E, Boshuisen M, Riedel WJ, Willekes C, Jolles J. The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology. 1999; 24:43-68.
26. File SE, Heard JE, Rymer J. Trough oestradiol levels associated with cognitive impairment in postmenopausal women after 10 years of oestradiol implants. Psychopharmacology (Berl). 2002; 161 (1):107-12.
27. Hogervorst E, Bandelow S. Should surgically menopausal women be treated with estrogens to decrease the risk for dementia? Invited Editorial. Neurology. 2007; 69(11):1070-1.
28. Hogervorst E, Bandelow S, Combrinck M, Irani M, Smith AD. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer’s disease and vascular dementia in post-mortem confirmed cases: added value of a decision-tree approach. Dementia. 2003; 16(3):170-80.
29. McKhann G, Drachmann D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34:939-44.
30. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991; 41:479-86.
31. Roth M, Huppert FA, Tym E, Mountjoy CQ. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge: Cambridge University Press, 1988.
32. Hogervorst E, Williams J, Combrinck M, Smith AD. Measuring serum oestradiol in women with Alzheimer’s disease: the importance of the sensitivity of the assay method. Eur J Endocrinol. 2003; 148(1):67-72.
33. Hogervorst E, Barnetson L, Williams J, et al. Women with dementia of Alzheimer’s type have higher levels of estradiol than healthy controls: prize winning poster. Paper presented at the 5th Annual Graylyn Conference on Women’s Health, 1999; Winston-Salem.
34. Paoletti AM, Congia S, Lello S, et al. Low androgenization index in elderly women and elderlymen with Alzheimer’s disease. Neurology. 2004; 62(2):301-3
35. Cunningham CJ, Sinnott M, Denihan A, et al. Endogenous sex hormone levels in postmenopausal women with AD. J Clin Endocrinol Metab. 2001; 86(3):1099-103.
36. Ravaglia G, Forti P, Maiolo F, et al. Endogenous sex hormones as risk factors for dementia in elderly men and women. J Gerontol A Biol Sci Med Sci. 2007; 62(9):1035-41.
37. Den Heijer T, Geerlings MI, Hofman A, et al. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol. 2003; 60(2):213-20.
38. Rees M. Gynaecological oncology perspective on management of the menopause. Eur J Surg Oncol. 2006; 32(8):892-7.
39. Berstein L, Zimarina T, Imyanitov E, et al. Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes. Maturitas. 2006; 54(4):352-5.
40. Szyllo K, Smolarz B, Romanowicz-Makowska H, Kulig A. The polymorphisms of the CYP17 and CYP19 genes in endometrial cancer patients. Pol J Pathol. 2006; 57(1):35-40.
41. Aban M, Arslan M, Tok E, et al. CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. Int J Gynecol Cancer. 2006; 16(1):448-51.
42. Kruman R, Wersto F, Cardozo-Pelaez L, et al. Cycle activation linked to neuronal cell death initiated by DNA damage. Neuron. 2004; 41(4):549-61.
43. Sharp L. CYP17 gene polymorphisms. A HuGE review. Am JEpid. 2004; 160(8):729-40.
44. Huang CS, Chern HD, Chang KJ, et al. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999; 59(19):4870-5.
45. Cecchin E. Lack of association of CYP1B1*3 polymorphism and ovarian cancer. Int J Biol Markers. 2004; 19(2):160-3.
46. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):94-101.
47. Turnbridge EM, Harrison PJ, Warden DR, et al. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(6): 996-9.
48. Wang PN. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. Dementia. 2005; 19(2/3):120-5.
49. Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. Neurology. 1999; 53(7): 1415-21.
50. Borroni B, Agosti C, Archetti S, et al. COMT polymorphism is associated with risk for psychosis in AD. Neurosci Lett. 2004; 370(2/3):127-9.
51. Wegienka G, Havstad S, Kelsey JL. Menopausal hormone therapy in a health maintenance organization before and after WHI hormone trials termination. J Women’s Health. 2006; 15(4):369-78.
52. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009; 21(1): CD003799. Review.
53. Hogervorst E, Williams JW, Budge M, Barnetson L, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro Endocrinol Lett. 2001; 22(3):163-8.
54. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004; 62(2):188-93.
55. Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone depletion and the development of Alzheimer disease. JAMA. 2004; 292(12):1431-2.
56. Hogervorst E, Lehmann DJ, Warden DR, McBroom J, Smith AD. Apolipoprotein E e4 and testosterone interact in the risk of Alzheimer’s disease in men. Int J Geriatr Psychiatry. 2002; 17(16):938-40.
57. Raber J, Bongers G, Le Fevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. Neurosci. 2002; 22(12):5204-9.
58. Lehmann DJ, Hogervorst E, Warden DR, et al. The androgen receptor CAG repeat and serum testosterone in the risk of Alzheimer’s disease in men. J Neurol Neurosurg Psychiatry. 2004; 75(1):163-4.
59. Krithivas K, Yurgalevitch SM, Mohr BA, et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol. 1999; 162(1):137-42.
60. Hogervorst E, Bandelow S, Moffat SD. Increasing testosterone levels and effects on cognitive function in elderly men and women: a review. Curr Drug Targets CNS Neurol Disord. 2005; 4(5): 531-40.